172 related articles for article (PubMed ID: 21494613)
1. An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
Jayakrishnan B; Hoke DE; Langendorf CG; Buckle AM; Rowley MJ
PLoS One; 2011 Apr; 6(4):e18411. PubMed ID: 21494613
[TBL] [Abstract][Full Text] [Related]
2. The PEVKEK region of the pyridoxal phosphate binding domain of GAD65 expresses a dominant B cell epitope for type 1 diabetes sera.
Tong JC; Myers MA; Mackay IR; Zimmet PZ; Rowley MJ
Ann N Y Acad Sci; 2002 Apr; 958():182-9. PubMed ID: 12021103
[TBL] [Abstract][Full Text] [Related]
3. Autoantigenic reactivity of diabetes sera with a hybrid glutamic acid decarboxylase GAD67-65 molecule GAD67(1-101)/GAD65(96-585).
Teoh KL; Fida S; Rowley MJ; Mackay IR
Autoimmunity; 1998; 28(4):259-66. PubMed ID: 9892508
[TBL] [Abstract][Full Text] [Related]
4. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes.
Ujihara N; Daw K; Gianani R; Boel E; Yu L; Powers AC
Diabetes; 1994 Aug; 43(8):968-75. PubMed ID: 8039604
[TBL] [Abstract][Full Text] [Related]
5. Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of coxsackievirus B4. Childhood Diabetes in Finland Study Group.
Lönnrot M; Hyöty H; Knip M; Roivainen M; Kulmala P; Leinikki P; Akerblom HK
Clin Exp Immunol; 1996 Jun; 104(3):398-405. PubMed ID: 9099922
[TBL] [Abstract][Full Text] [Related]
6. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes.
Hampe CS; Hammerle LP; Bekris L; Ortqvist E; Kockum I; Rolandsson O; Landin-Olsson M; Törn C; Persson B; Lernmark A
J Clin Endocrinol Metab; 2000 Dec; 85(12):4671-9. PubMed ID: 11134126
[TBL] [Abstract][Full Text] [Related]
7. Association between antibodies to the MR 67,000 isoform of glutamate decarboxylase (GAD) and type 1 (insulin-dependent) diabetes mellitus with coexisting autoimmune polyendocrine syndrome type II.
Seissler J; Bieg S; Yassin N; Mauch L; Northemann W; Boehm BO; Scherbaum WA
Autoimmunity; 1994; 19(4):231-8. PubMed ID: 7578849
[TBL] [Abstract][Full Text] [Related]
8. Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognition.
Primo ME; Anton EA; Villanueva AL; Poskus E; Ermácora MR
Clin Immunol; 2003 Jul; 108(1):38-45. PubMed ID: 12865069
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.
Seissler J; Amann J; Mauch L; Haubruck H; Wolfahrt S; Bieg S; Richter W; Holl R; Heinze E; Northemann W
J Clin Invest; 1993 Sep; 92(3):1394-9. PubMed ID: 8376591
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes.
Lühder F; Schlosser M; Mauch L; Haubruck H; Rjasanowski I; Michaelis D; Kohnert KD; Ziegler M
Autoimmunity; 1994; 19(2):71-80. PubMed ID: 7772705
[TBL] [Abstract][Full Text] [Related]
11. Immune reactivity to GAD25 in type 1 diabetes mellitus.
Chessler SD; Hampe CS; Ortqvist E; Simonson WT; Bekris L
Autoimmunity; 2002 Aug; 35(5):335-41. PubMed ID: 12515288
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to glutamic acid decarboxylase and P2-C peptides in sera from coxsackie virus B4-infected mice and IDDM patients.
Hou J; Said C; Franchi D; Dockstader P; Chatterjee NK
Diabetes; 1994 Oct; 43(10):1260-6. PubMed ID: 7523207
[TBL] [Abstract][Full Text] [Related]
13. Glutamic acid decarboxylase-67 (GAD67): expression relative to GAD65 in human islets and mapping of autoantibody epitopes.
Cram DS; Faulkner-Jones B; Kun J; Harrison LC
Endocrinology; 1995 Mar; 136(3):1111-9. PubMed ID: 7532577
[TBL] [Abstract][Full Text] [Related]
14. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes.
Daw K; Powers AC
Diabetes; 1995 Feb; 44(2):216-20. PubMed ID: 7532143
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase.
Hagopian WA; Michelsen B; Karlsen AE; Larsen F; Moody A; Grubin CE; Rowe R; Petersen J; McEvoy R; Lernmark A
Diabetes; 1993 Apr; 42(4):631-6. PubMed ID: 8454115
[TBL] [Abstract][Full Text] [Related]
16. COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity.
Fenalti G; Hampe CS; Arafat Y; Law RH; Banga JP; Mackay IR; Whisstock JC; Buckle AM; Rowley MJ
Diabetes; 2008 May; 57(5):1293-301. PubMed ID: 18184926
[TBL] [Abstract][Full Text] [Related]
17. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP
J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351
[TBL] [Abstract][Full Text] [Related]
18. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.
Ziegler B; Schlosser M; Lühder F; Strebelow M; Augstein P; Northemann W; Powers AC; Ziegler M
Acta Diabetol; 1996 Sep; 33(3):225-31. PubMed ID: 8904930
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.
Powers AC; Bavik K; Tremble J; Daw K; Scherbaum WA; Banga JP
Clin Exp Immunol; 1999 Dec; 118(3):349-56. PubMed ID: 10594551
[TBL] [Abstract][Full Text] [Related]
20. Antigenic determinants to GAD autoantibodies in patients with type 1 diabetes with and without autoimmune thyroid disease.
Park H; Yu L; Kim T; Cho B; Kang J; Park Y
Ann N Y Acad Sci; 2006 Oct; 1079():213-9. PubMed ID: 17130557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
